IBRX Stock Overview
A clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ImmunityBio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.65 |
| 52 Week High | US$10.53 |
| 52 Week Low | US$1.25 |
| Beta | -0.23 |
| 1 Month Change | 45.16% |
| 3 Month Change | 61.73% |
| 1 Year Change | 174.19% |
| 3 Year Change | -51.27% |
| 5 Year Change | n/a |
| Change since IPO | -80.23% |
Recent News & Updates
Recent updates
ImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer Battle
Apr 23ImmunityBio: Financial And Regulatory Risks Outweigh Anktiva's Promise
Feb 27ImmunityBio: Buy Low Now Vs. Buy High Later
Feb 11ImmunityBio: PDUFA Pending
Oct 17ImmunityBio: Compelling Data In Bladder Cancer, Yet Funding Issues Remain
Aug 07ImmunityBio: Ready To Shift Gears After Long-Awaited BLA Submission
Jun 02ImmunityBio: Extensive Pipeline, NDA Expected For Anktiva This Quarter
Mar 15ImmunityBio: Company Leaves 2021 On A High-Note; Share Price Still Falls Flat
Dec 27ImmunityBio: Demoralization Of The Bulls By Deflating The Share Price
Oct 12ImmunityBio: Market Has Lost Contact Following Merger
Jul 19Shareholder Returns
| IBRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.4% | 2.2% | 1.8% |
| 1Y | 174.2% | 5.8% | 26.1% |
Return vs Industry: IBRX exceeded the US Biotechs industry which returned 5.8% over the past year.
Return vs Market: IBRX exceeded the US Market which returned 26.1% over the past year.
Price Volatility
| IBRX volatility | |
|---|---|
| IBRX Average Weekly Movement | 22.4% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: IBRX's share price has been volatile over the past 3 months.
Volatility Over Time: IBRX's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 628 | Rich Adcock | immunitybio.com |
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company’s platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme.
ImmunityBio, Inc. Fundamentals Summary
| IBRX fundamental statistics | |
|---|---|
| Market cap | US$5.29b |
| Earnings (TTM) | -US$600.96m |
| Revenue (TTM) | US$302.00k |
Over9,999x
P/S Ratio-8.8x
P/E RatioIs IBRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBRX income statement (TTM) | |
|---|---|
| Revenue | US$302.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$302.00k |
| Other Expenses | US$601.26m |
| Earnings | -US$600.96m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.87 |
| Gross Margin | 100.00% |
| Net Profit Margin | -198,994.04% |
| Debt/Equity Ratio | -123.2% |
How did IBRX perform over the long term?
See historical performance and comparison